TESTING ITS IMMUNOTHERAPEUTIC POTENTIAL THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP PROCESSES FOR THE PRODUCTION OF B-CELL GROWTH FACTOR (BCGF) AND TO TEST THE POTENTIAL APPLICATIONS OF BCGF FOR THE TREATMENT OF HUMAN IMMUNOPATHOLOGICAL

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3031
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Collaborative Research Inc
128 Spring St., Lexington, MA, 02173
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SUSAN K. KEESEE
PRINCIPAL INVESTIGATOR
(617) 861-9700
Business Contact:
() -
Research Institution:
n/a
Abstract
TESTING ITS IMMUNOTHERAPEUTIC POTENTIAL THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP PROCESSES FOR THE PRODUCTION OF B-CELL GROWTH FACTOR (BCGF) AND TO TEST THE POTENTIAL APPLICATIONS OF BCGF FOR THE TREATMENT OF HUMAN IMMUNOPATHOLOGICAL CONDITIONS. BCGF MAY BE USEFUL AS AN IMMUNOTHERAPEUTIC AGENT IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASES AND POSSIBLY IN CERTAIN B-CELL LEUKEMIAS. THE PRINCIPAL GOAL OF THE FIRST PHASE OF THIS PROJECT IS TO DEVELOP A CONTINUOUS B-CELL LINE WHICH CAN BE USED TO FACILITATE THE LARGE-SCALE PURIFICATION OF BCGF. FRESHLY ISOLATED B CELLS FROM NORMAL HUMAN DONORS WILL BE PLACED INTO AN INITIAL SUSPENSION CULTURE. CULTURED CELLS WILL THEN BE CLONED IN SOFT AGAR AND RECLONED BY LIMITING DILUTION. B-CELL LINES WILL BE MAINTAINED WITH PARTIALLY PURIFIED BCGF ALREADY DEVELOPED AT COLLABORATIVE RESEARCH. IT IS ANTICIPATED THAT A BCGF-DEPENDENT CELL LINE WILL BE DEVELOPED DURING PHASE I. THIS LINE WILL BE USED TO DEVELOP A SIMPLE, RAPID AND REPRODUCIBLE ASSAY FOR THE DETECTION OF BCGF. IN PHASE II, METHODS WILL BE DEVELOPED TO PURIFY BCGF IN AMOUNTS SUFFICIENT FOR BIOCHEMICAL/BIOLOGICAL CHARACTERIZATION STUDIES AND FOR EVENTUAL CLINICAL EVALUATION AS AN IMMUNOAUGMENTATIVE AGENT IN THE TREATMENT OF IMMUNODEFICIENCY DISEASES AND B-CELL LEUKEMIAS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government